| Amlodipine besilate |
![]() Last updated: 14/09/2025 |
![]() |
(Also known as: amlodipine besylate; amlodipine benzenesulfonate) |
|
|
|
A veterinary and human drug used to slow the heart beat and relax blood vessel walls | |
|---|---|---|
|
Typically used to treat secondary hypertension caused by hyperthyroidism, diabetes, kidney disease or cardiomyopathy. | |
|
Cats; Dogs |
| Approval status |
|
Approved - usually available as a prescription only medicine to be authorised by a veterinarian (POM-V) | |
|---|---|---|
|
Approved |
| Chemical structure |
|
Amlodipine besilate exhibits stereoisomerism, specifically chirality, due to the presence of a single chiral centre in its dihydropyridine ring system. This chiral centre gives rise to two enantiomers: the (S)-amlodipine and (R)-amlodipine forms. Among these, the (S)-enantiomer is pharmacologically more active. Most commercial formulations of amlodipine besilate are racemic mixtures. | |
|---|---|---|
|
C₂₆H₃₁ClN₂O₈S | |
|
CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.C1=CC=C(C=C1)S(=O)(=O)O | |
|
- | |
|
ZPBWCRDSRKPIDG-UHFFFAOYSA-N | |
|
InChI=1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9) | |
|
Yes |
|
|
| Common Name | Relationship | Link |
|---|---|---|
| amlodipine besilate | - | ![]() |
| amlodipine besilate dihydrate | Hydrate | ![]() |
| General status |
|
Medicinal drug: Vasodilator agent | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dihydropyridine | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
Synthetic | ||||||||||||||
|
Amlodipine slows the rate at which calcium moves into the heart and blood vessel walls. Calcium channel blocker. | ||||||||||||||
|
[Voltage-dependent L-type calcium channel subunit alpha-1C, Inhibitor], [Voltage-dependent calcium channel subunit alpha-2/delta-1, Inhibitor], [Voltage-dependent L-type calcium channel subunit beta-2 , Inhibitor], [Voltage-dependent L-type calcium channel subunit alpha-1D, Inhibitor] | ||||||||||||||
|
111470-99-6 | ||||||||||||||
|
658-042-6 | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
60496 | ||||||||||||||
|
Lipid modifying agent: HMG CoA reductase inhibitors, other combinations | ||||||||||||||
|
QC10BX11 | ||||||||||||||
|
No | ||||||||||||||
|
- | ||||||||||||||
|
567.1 | ||||||||||||||
|
- | ||||||||||||||
|
benzenesulfonic acid; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate | ||||||||||||||
|
- | ||||||||||||||
|
|
||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
- | ||||||||||||||
|
|||||||||||||||
| Commercial |
|
|
|||
|---|---|---|---|---|
|
Current | |||
|
1986, first approved USA | |||
|
|
|||
|
|
|||
|
Usually formulated as tablets for oral administration | |||
|
Amlodipine besilate is synthesised through a multi-step chemical process that begins with the formation of the 1,4-dihydropyridine ring, the core structure of the molecule. This is typically achieved via a Hantzsch reaction, where an aldehyde, a beta-ketoester, and an amine, such as 2-aminobenzyl alcohol, are condensed under controlled temperature and solvent conditions. The resulting amlodipine base is then purified and subjected to salification by reacting with besilic acid to form the besilate salt. | |||
|
Published GHG data is not available for most pharmaceuticals. However, according to industry, global averages suggest producing 1 kg of a typical active pharmaceutical ingredient can range from 10 to 100 kg CO₂e for small molecule drugs and potentially up to 1000 kg CO₂e for complex biologicals such as vaccines, depending on the drug type, its formulation, complexity of synthesis, solvent recovery, and energy sources used. |
|
|
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
| - | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
| Degradation |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- | ||||||||||
| Soil adsorption and mobility |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
| Fate indices |
|
|
|
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - | |||||||||||||||||||||||||||
| Known metabolites |
None
|
|
| Terrestrial ecotoxicology |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
37 | V3 V = ChemID Online Databases; Chemspider; PubChem. (ChemID ) Mouse3 = Unverified data of known source |
High | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
| - | |||||||||||
|
- | - | - | ||||||||
| - | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- |
|
- | - | - | ||||||
|
- | ||||||||||
| Aquatic ecotoxicology |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - | ||||||||
|
|
| General |
|
|
|
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
37 | V3 V = ChemID Online Databases; Chemspider; PubChem. (ChemID ) Mouse3 = Unverified data of known source |
High | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Heptic metabolism. Renal excretion accounts for approx. 60% administered. The remainder is eliminated in bile and faeces. | V3 V = ChemID Online Databases; Chemspider; PubChem. (ChemID ) 3 = Unverified data of known source |
- | ||||||||
| Health issues |
|
|
||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
May cause swelling of ankles or feet May cause difficult or laboured breathing Possible liver & heart toxicant |
||||||||||||||||||||||||||||
| Handling issues |
|
|
|||
|---|---|---|---|---|
|
Will release toxic gases if heated to decomposition Slightly flammable. May combust at high temperatures |
|||
|
Health: H301, H318, H373 Environment: H400, H410 |
|||
|
Not listed (Not listed) | |||
|
- | |||
|
- | |||
|
- |
|
|
|
|
||
|---|---|---|---|
|
amlodipine besilate | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
| Record last updated: | 14/09/2025 |
| Contact: | aeru@herts.ac.uk |
| Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |
© Copyright University of Hertfordshire, 2006-2026. All Rights Reserved
Your use of this website and its various databases is subject to the terms detailed in the University of Hertfordshire’s copyright and IPR statement that can be found at https://www.herts.ac.uk/about-us/legal. In addition, your use of this website and its various databases is subject to the terms of this additional Copyright Statement and the database Conditions of use document. Unless explicitly stated otherwise, the content of this website and databases are owned and controlled by the University of Hertfordshire. Site content, including its selection and arrangement, is owned by the University of Hertfordshire and is protected by copyright and other laws. Except as otherwise expressly permitted under copyright law or within the database Conditions of Use document, the content of this site may not be copied, reproduced, republished, downloaded, posted, broadcast or transmitted in any way without first obtaining the University of Hertfordshire’s written permission. By using our databases the user is deemed to have agreed to comply with all of the terms and conditions as described above and within all relevant documentation.





